Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma-Reference-Cited by-同舟云学术

Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma

Published:2015-09-11 Issue:4 Volume:5 Page:e1085147
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Castino Giovanni Francesco,Cortese Nina,Capretti Giovanni,Serio Simone,Di Caro Giuseppe,Mineri Rossana,Magrini Elena,Grizzi Fabio,Cappello Paola,Novelli Francesco,Spaggiari Paola,Roncalli Massimo,Ridolfi Cristina,Gavazzi Francesca,Zerbi Alessandro,Allavena Paola,Marchesi Federica

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/2162402X.2015.1085147

Reference52 articles.

1. Cancer statistics, 2014

2. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

3. Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to Invasion

4. Inflammatory networks and immune surveillance of pancreatic carcinoma

5. Activated Pancreatic Stellate Cells Sequester CD8+ T Cells to Reduce Their Infiltration of the Juxtatumoral Compartment of Pancreatic Ductal Adenocarcinoma

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Tumor Microenvironment in Pancreatic Cancer Immunotherapy: Current Status and Future Perspectives;International Journal of Molecular Sciences;2024-09-03

2. The tumor immune microenvironment in resected treatment-naive pancreatic cancer patients with long-term survival;Pancreatology;2024-08

3. The roles of tertiary lymphoid structures in genitourinary cancers: a comprehensive review of current advances and clinical applications;International Journal of Surgery;2024-07-08

4. Impact of tertiary lymphoid structures on prognosis and therapeutic response in pancreatic ductal adenocarcinoma;HPB;2024-07

5. Integrating metabolic profiling of pancreatic juice with transcriptomic analysis of pancreatic cancer tissue identifies distinct clinical subgroups;Frontiers in Oncology;2024-06-26